Displaying drugs 101 - 125 of 406 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Daratumumab | 145391.67 C6466H9996N1724O2010S42 |  | A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. | Antibodies, Monoclonal / CD38 (Clusters of Differentiation 38) inhibitors |
| Canakinumab | 145157.0 C6452H9958N1722O2010S42 |  | An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). | Interleukin Inhibitors |
| Atoltivimab | 145097.54 C6448H9954N1726O2002S44 |  | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. | Antiviral Agents |
| Siltuximab | 145000.0 C6450H9932N1688O2016S50 |  | An interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative. | Interleukin Inhibitors |
| Dinutuximab | 145000.0 C6422H9982N1722O2008S48 | | An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. | Antibodies, Monoclonal |
| Atezolizumab | 145000.0 | | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Ocrelizumab | 145000.0 C6494H9978N1718O2014S46 | | A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. | Selective Immunosuppressants |
| Denosumab | 144700.0 C6404H9912N1724O2004S50 |  | A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. | Antibodies, Monoclonal, Humanized / Bone Density Conservation Agents / RANK Ligand Inhibitor |
| Tildrakizumab | 144400.0 C6426H9918N1698O2000S46 | | An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. | Interleukin Inhibitors |
| Adalimumab | 144190.3 C6428H9912N1694O1987S46 |  | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| Infliximab | 144190.3 C6428H9912N1694O1987S46 |  | A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| Burosumab | 144100.0 C6388H9904N1700O2006S46 | | A fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia. | Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Blood Proteins / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Fibroblast Growth Factor-23 Blocking Antibodies / Globulins / Immunoglobulins / Immunoproteins / Musculo-Skeletal System / Proteins / Serum Globulins |
| Dostarlimab | 144000.0 C6420H9832N1680O2014S44 | | An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers and solid tumours with no alternative treatment options. | PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Naxitamab | 144000.0 | | A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. | Glycolipid Disialoganglioside-directed Antibody |
| Maftivimab | 143948.11 C6368H9886N1706O2008S46 | | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. | Antiviral Agents |
| Rituximab | 143859.7 C6416H9874N1688O1987S44 |  | A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. | Antibodies, Monoclonal / CD20 (Clusters of Differentiation 20) inhibitors |
| Tositumomab | 143859.7 C6416H9874N1688O1987S44 |  | A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. | Iodine (131I) Compounds |
| Basiliximab | 143801.3 C6378H9844N1698O1997S48 |  | A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients. | Interleukin Inhibitors |
| Ramucirumab | 143600.0 C6374H9864N1692O1996S46 |  | An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. | Angiogenesis Inhibitors / Antibodies, Monoclonal / VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors |
| Nivolumab | 143597.3811 C6362H9862N1712O1995S42 |  | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Ibritumomab tiuxetan | 143375.5 C6382H9830N1672O1979S54 |  | A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. | Various Therapeutic Radiopharmaceuticals |
| Eptinezumab | 143000.0 | | A monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults. | Calcitonin Gene-related Peptide Antagonist |
| Satralizumab | 143000.0 | | A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD). | Interleukin Inhibitors |
| Raxibacumab | 142844.5367 C6320H9794N1702O1998S42 |  | A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate. | Antibacterial monoclonal antibodies / Specific Immunoglobulins |
| Human immunoglobulin G | 142682.3 C6332H9826N1692O1980S42 |  | A purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders. | Antibodies / Human Immunoglobulin G / Immunoglobulin G / Immunoglobulins / Immunologic Factors / Immunoproteins / Serum Globulins |
Displaying drugs 101 - 125 of 406 in total